AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05048199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: volume-controlled mode of ventilation
Description: Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6).
Study NCT04854577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid Free Anesthesia
Description: Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
Study NCT05865262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula.
Study NCT05865262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test (assessing ionic and hormonal circulating levels)
Description: Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
Study NCT04854577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Anesthetic Regimen
Description: Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
Study NCT05225480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness perception conversation
Description: A conversation based on the indvidual's knee pain related illness perceptions
Study NCT05225480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: research motivation conversation
Description: A conversation based on the indvidual's motivation for participating in research
Study NCT05214495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical oral Omega-3 hydrogel
Description: Topical oral Omega-3 hydrogel prepared from fish oil
Study NCT05214495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional preventive treatment
Description: topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)
Study NCT05560477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM3101
Description: Injectable drug product.
Study NCT05560477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 2 mL 0.9% normal saline
Study NCT04847011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05359315 — intervention group
Intervention type: DRUG
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT06123715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
Study NCT06123715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
Study NCT05607602 — intervention group
Intervention type: OTHER
Intervention: Comparison of blood samples between the two groups
Description: In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
Study NCT05165732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 1
Description: Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT05165732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 2
Description: Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT05165732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 3
Description: Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT05343715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fabrazyme (agalsidase beta) 1 mg/kg
Description: Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Study NCT06497751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based Dyadic Coping Group
Description: Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization.
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid
Study NCT05070455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asceniv™
Description: Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g tid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g tid
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 0.1g bid
Study NCT05716867 — intervention group
Intervention type: BIOLOGICAL
Intervention: Measurement of salivary cystatin S protein levels in saliva
Description: The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
Study NCT05744856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care with informal support
Description: The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition.
Study NCT06374927 — intervention group
Intervention type: DEVICE
Intervention: Rehabilitation Gaming System (VR-based mobile application)
Description: The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
Study NCT05656183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TruGenome Cardiovascular Disease test
Description: The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
Study NCT06282445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
Study NCT06282445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, ivgtt, d1, Q3W
Study NCT06282445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
Study NCT06282445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg，ivgtt, d1, Q3W
Study NCT04777006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4
Study NCT04971070 — intervention group
Intervention type: OTHER
Intervention: Observation and follow-up
Description: Observation and follow-up study
Study NCT04777006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy
Description: Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care.
Study NCT05850819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal silver gelatin sponge
Description: Augment the extraction socket with Gelatamp
Study NCT05850819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile gauze pack
Description: Extraction socket allowed to heal without augmentation with any material
Study NCT04741113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An online 15-minute educational module
Description: An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion
Study NCT05043272 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.
Study NCT05178459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathy measurement
Description: Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
Study NCT06058767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Otoacoustic Emissions Testing
Description: An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
Study NCT06058767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pure Tone Audiometry
Description: The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
Study NCT06407453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: There will be no interference ergonomics training
Study NCT06407453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
Study NCT06227533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin
Description: regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
Study NCT05061732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid
Study NCT05713175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVA plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
Study NCT05756023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the pregnancy rate at IVF / ICSI cycles
Description: To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
Study NCT05713175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
Study NCT04833946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis paniculata [150 mg]
Description: One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
Study NCT04833946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose (MCC)
Description: One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
Study NCT05870969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance every 3 months
Description: Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
Study NCT05870969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance every 6 months
Description: Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
Study NCT05870969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance annually
Description: Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
Study NCT04783311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval
Study NCT04783311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval
Study NCT04783311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval
Study NCT05713175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixtoe device
Description: Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
Study NCT06471959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
Study NCT05703724 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AI algorithm for the detection of glaucoma
Description: The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
Study NCT03749928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OstiSense biosensor - active
Description: The activated biofeedback back night guard will be used to reduce sleep bruxism
Study NCT03749928 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OstiSensor biosensor - not activated
Description: A not-activated night guard will be used as control device
Study NCT06521827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course radiotherapy
Description: short course palliative radiotherapy
Study NCT05234918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Rotary File Systems
Description: * Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6